Moberg Pharma’s nomination committee appointed

Moberg Pharma’s nomination committee appointed

STOCKHOLM, November 3^rd, 2022 – In accordance with the resolution of the Annual General Meeting on May 16^th, 2022, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 16^th, 2022.

Moberg Pharma’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2022 comprises:

·    Gillis Cullin, appointed by Östersjöstiftelsen

·    Fredrik Åsberg

·    Martin Öhrn, appointed by Anders Lundmark

·    Kerstin Valinder Strinnholm, Chairman of the Board

Together, the Nomination Committee represents 12.6 percent of the shares in Moberg Pharma as of September 30^th, 2022.

The Nomination Committee shall submit proposals for the fiscal year January – December 2022 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

The Annual General Meeting for the fiscal year January – December 2022 will be held on May 16^th 2023.